EP2147103B1 SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
失效 - 权利终止
转让
基本信息:
- 专利标题： SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
- 申请号：EP07821575.3 申请日：2007-10-19
- 公开(公告)号：EP2147103B1 公开(公告)日：2018-12-12
- 发明人： ØRUM, Henrik , SAZANI, Peter, L.
- 申请人： Roche Innovation Center Copenhagen A/S , Ercole Biotech, INC.
- 申请人地址： Fremtidsvej 3 2970 Hørsholm DK
- 专利权人： Roche Innovation Center Copenhagen A/S,Ercole Biotech, INC.
- 当前专利权人： ROCHE INNOVATION CENTER COPENHAGEN A/S
- 当前专利权人地址： ROCHE INNOVATION CENTER COPENHAGEN A/S
- 代理机构： D Young & Co LLP
- 优先权： PCT/US2007/010556 20070501; US799117 20070501
- 国际公布： WO2008131807 20081106
- 主分类号： C12N15/113
- IPC分类号： C12N15/113 ; A61K31/712 ; A61K31/7125 ; C07K14/715 ; C07H21/04 ; A61K48/00
摘要：
The present invention relates to splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has thereputic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.